Suchergebnisse - "Iribarren, José Antonio"

PubPharm (6)

1

Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice

enthalten in: The Journal of antimicrobial chemotherapy | 2023

von Suárez-García, I. | Alejos, B. | Hernando, V. | +111

2

Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV : Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic

enthalten in: Viruses | 2023

von Buzón, L. | Dueñas, C. | Pedrero, R. | +14

3

Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection

enthalten in: AIDS (London, England) | 2022

von Del Amo, J. | Polo, R. | Moreno, S. | +14

4

Use of Generic Antiretroviral Drugs and Single-Tablet Regimen De-Simplification for the Treatment of HIV Infection in Spain

enthalten in: AIDS research and human retroviruses | 2022

von Ruiz-Algueró, M. | Alejos, B. | García Yubero, C. | +110

5

Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens

enthalten in: Frontiers in immunology | 2022

von Serrano-Villar, S. | López-Huertas, M. | Jiménez, D. | +12

CommentIn: Front Immunol. 2022 Apr 29;13:904689. - PMID 35572577

6

Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine : results of the neurocognitive substudy of the SALT randomized clinical trial

enthalten in: The Journal of antimicrobial chemotherapy | 2018

von Pérez-Valero, I. | Pasquau, J. | Rubio, R. | +112

1
[1]